Loading
Cancer Genomics and Diagnostics / Cancer Cells and Metastasis · Journal article
International Journal of Medicine and Pharmaceutical Research · August 10, 2026
A consensus or society position rather than new primary data.
This is a narrative review of pharmacological advances in targeted cancer therapy and precision oncology, synthesizing evidence on molecular diagnostics, biomarker testing, and therapeutic classes without presenting original trial data or quantified efficacy comparisons. It characterizes the current state of the field and identifies challenges (drug resistance, tumor heterogeneity, access barriers, cost) and emerging tools (antibody-drug conjugates, liquid biopsy, multi-omics, AI) as opportunities for clinical advancement.
Narrative review. Literature on targeted cancer therapies, precision oncology, and related molecular diagnostics across cancer types. Intervention: Targeted cancer therapies including antibody-drug conjugates, kinase inhibitors, and biomarker-guided treatment strategies.
Targeted therapies improve treatment precision by selectively interfering with cancer-related molecular pathways and reducing damage to normal tissues Precision oncology integrates molecular diagnostics, pharmacogenomics, biomarker testing, and companion diagnostics to support individualized treatment selection Emerging technologies including antibody-drug conjugates, liquid biopsy, multi-omics, and artificial intelligence are highlighted as contributors to personalized cancer care
Precision oncology integrates molecular diagnostics, pharmacogenomics, biomarker testing, and companion diagnostics to support individualized treatment selection
This review provides clinicians and researchers with a synthesis of current pharmacological approaches to precision oncology and identifies emerging diagnostic and therapeutic tools that may enhance personalized cancer management. The described challenges (access, cost, resistance mechanisms) remain barriers to broader clinical implementation.
This is a narrative review synthesizing pharmacological advances in precision oncology without presenting new primary data or controlled comparisons, suitable for informing clinical understanding but not establishing new evidence of efficacy.
As stated by the source record.
This review provides clinicians and researchers with a synthesis of current pharmacological approaches to precision oncology and identifies emerging diagnostic and therapeutic tools that may enhance personalized cancer management. The described challenges (access, cost, resistance mechanisms) remain barriers to broader clinical implementation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Cancer remains one of the major causes of morbidity and mortality worldwide and it creates a continuous need for more effective and personalized treatment strategies. Targeted cancer therapy has changed the field of oncology by focusing on specific molecular abnormalities involved in tumor growth, survival, and progression. By selectively interfering with cancer-related molecular pathways, targeted therapies can improve treatment precision and reduce unnecessary damage to normal tissues. Precision oncology brings together molecular diagnostics, pharmacogenomics, biomarker testing, and companion diagnostics to support individualized treatment selection and improve clinical outcomes. This narrative review summarizes recent pharmacological advances in targeted cancer therapy and examines their role in precision oncology. A structured literature search was conducted using major scientific databases and authoritative sources, with emphasis on peer-reviewed articles, clinical studies, and international guidance related to targeted therapies, molecular biomarkers, pharmacogenomics, and precision medicine. The review covers the molecular basis of precision oncology, major classes of targeted anticancer agents, predictive biomarkers, companion diagnostics, and clinical applications across different cancer types. Mechanisms responsible for drug resistance and emerging therapeutic strategies are also discussed. Recent developments in antibody-drug conjugates, liquid biopsy, multi-omics technologies, and artificial intelligence are highlighted for their potential contribution to more personalized cancer care. Several challenges continue to affect the clinical use of targeted therapies like drug resistance, tumor heterogeneity, limited access to molecular testing, and the high cost of treatment. Additionally, progress in fields of molecular pharmacology, biomarker-guided treatment, and innovative therapeutic strategies may expand the clinical applications of precision oncology. Overall, targeted cancer therapy gradually strengthens personalized cancer management and remains an important area for future oncology research and clinical practice.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.